A post-hoc analysis of data from the TREX-AMD trial has determined that eyes with neovascular age-related macular degeneration and treated with ranibizumab, develop more macular atrophy lesions within baseline choroidal neovascularization regions than outside those regions.
Study results demonstrate that low-dose proton beam irradiation may enhance and extend the effects of anti-vascular endothelial growth factor (anti-VEGF) therapy for age-related macular degeneration.
The REGENXBIO drug's promising phase 1 results has led to the addition of a fourth patient dosing cohort and a phase 2 trial initiation.
Recent research suggests that reticular pseudodrusen may be associated with the progression of early AMD to GA. Although an association has been theorized between pseudodrusen and AMD, researchers remain unclear on the pathogenesis of reticular pseudodrusen.
People who ate at least 1 serving of oranges every day had more than a 60% reduced risk of developing late-stage macular degeneration in that time period.
The DR market is expected to accrue a sum of $2,490 million by 2022, growing at a compound annual growth rate of 14.4% from 2014-2022.
Risk of scar development increased from three-fold at 2 years to 4.5-fold at 5 years, possibly as a result of treated quiescent classic lesions that relapsed over time.
How come treat-and-extend may not be the most ideal therapy regimen for retina disease, and how biologics change physicians' perspective on dosing.
Are anti-VEGF and PRP therapies the best-case scenario for patients with AMD, or will gene therapies reach the market in the near future?
How the three-year results of a gene therapy for inherited retinal disease may redefine its potential in ophthalmology.
Patients who were treated with CLS-TA were able to achieve ≥3 lines of visual acuity 47% of the time, compared to 15% of the patients who received sham treatment.
Those who were switched to aflibercept improved 9 letters of VA, and 110 µm in CST from months 6 to 12.
After 6 months, 80% of those implanted with the 100 mg/mL dose of ranibizumab still did not need a medication refill.
A comparison of patients with either anterior segment neovascularization without glaucoma or neovascular glaucoma found the benefits of anti-VEGF and PRP are heavily influenced by the presence of glaucoma.
A three-year update of VN for patients with biallelic RPE65 mutation-associated inherited retinal disease improved on the common standard-of-care for retina disease.
Results from the PACORES group clinical trial debunked previously-held beliefs that IVB is unsafe for patients with proliferative diabetic retinopathy undergoing the procedure.
Why substantial evidence is lacking to indicate either therapy method's preference for the treatment of neovascularization.
The use of a single drop of nepafenac 0.3% suspension has shown in a trial to be an effective pain reducer post-intravitreal injection at both 6-hour and 24-hour points.
The cheaper intravitreal anti-VEGF options improved visual acuity in the eyes of patients with 5 different retinal conditions.
Amy S. Babicuh, MD, noted that “while DRIL is not the biomarker, it is certainly useful in conjunction with other information, and should prompt continued treatment with anti-VEGF agents when it is present.”
The modeled and lifetime QALY costs in the facility and out of the facility were $181,144 and $107,965, respectively, for PPV.
A population-based cohort study identified that patients with insomnia developed AMD at a rate 0.7% higher than those who did not.
How improvements to patient education, drug costs, and biosimilar therapy availability could keep patients with retina disease away from risky procedures.
Telemedicine screenings provided by a primary care office in an urbanized setting over 2 years showed patients had an 81.9% compliance capture rate—a significant improvement from previous studies in the same field.
The number of anti-VEGF injections patients underwent per 28 days decreased from 0.322 to 0.047 after FAc implantation.
